Bank of New York Mellon Corp Increases Position in Fractyl Health, Inc. (NASDAQ:GUTS)

Bank of New York Mellon Corp lifted its holdings in Fractyl Health, Inc. (NASDAQ:GUTS) by 54.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 64,020 shares of the company’s stock after buying an additional 22,572 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.13% of Fractyl Health worth $76,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in Fractyl Health in the 4th quarter valued at $34,000. Sei Investments Co. purchased a new stake in shares of Fractyl Health during the fourth quarter valued at $57,000. Norges Bank bought a new position in shares of Fractyl Health in the fourth quarter worth about $206,000. Geode Capital Management LLC grew its holdings in shares of Fractyl Health by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 513,079 shares of the company’s stock worth $1,057,000 after purchasing an additional 11,603 shares during the last quarter. Finally, Silverarc Capital Management LLC increased its stake in Fractyl Health by 6.2% in the 4th quarter. Silverarc Capital Management LLC now owns 176,922 shares of the company’s stock worth $364,000 after buying an additional 10,256 shares during the period.

Fractyl Health Stock Down 46.0%

Shares of NASDAQ:GUTS opened at $1.01 on Thursday. The business’s 50 day moving average is $1.84 and its 200 day moving average is $1.60. The stock has a market cap of $49.47 million, a P/E ratio of -0.55 and a beta of 1.66. Fractyl Health, Inc. has a 52-week low of $0.83 and a 52-week high of $3.72. The company has a quick ratio of 2.50, a current ratio of 2.50 and a debt-to-equity ratio of 4.61.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 13th. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49). Fractyl Health had a negative return on equity of 228.66% and a negative net margin of 73,864.52%. Sell-side analysts predict that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group initiated coverage on shares of Fractyl Health in a research report on Tuesday, April 15th. They issued a “buy” rating and a $12.00 price objective for the company.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.